BINSA Act

The Biotech Investment National Security Act (BINSA) amends the Defense Production Act to subject biotechnology transactions to federal outbound investment screening, specifically targeting investments and licensing agreements involving Chinese entities. The bill defines the covered biotechnology sector to include pharmaceuticals, biological products, and therapeutic compounds, while explicitly excluding agricultural biotechnology, industrial fermentation unrelated to therapeutics, and basic academic research. It requires the Secretary of the Treasury to issue regulations within one year that prioritize scrutiny of intellectual property licensing, joint ventures, and equity investments that transfer innovation capacity or manufacturing know-how to China. Additionally, the legislation mandates that the Secretary of Defense submit a report to Congress within 60 days assessing whether U.S. capital flows into Chinese biotechnology negatively impact national security.